Compare · LLY vs PRGO
LLY vs PRGO
Side-by-side comparison of Eli Lilly and Company (LLY) and Perrigo Company plc (PRGO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PRGO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.03T, about 729.5x PRGO ($1.42B).
- Over the past year, LLY is up 44.0% and PRGO is down 61.3% - LLY leads by 105.4 points.
- Both names hit the wire about 15 times in the past 4 weeks.
- LLY has more recent analyst coverage (25 ratings vs 11 for PRGO).
- Company
- Eli Lilly and Company
- Perrigo Company plc
- Price
- $1098.76-1.20%
- $10.25+0.89%
- Market cap
- $1.03T
- $1.42B
- 1M return
- +7.60%
- -3.44%
- 1Y return
- +44.02%
- -61.34%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 15
- 15
- Recent ratings
- 25
- 11
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, and Dr. Fresh. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations in the United States, as well as pharmaceutical and diagnostic products in Israel. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Latest LLY
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,401 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,723 units (SEC Form 4)
- Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
- FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
Latest PRGO
- Director Parker Geoffrey M. exercised 976 units of Ordinary Shares at a strike of $10.99 and covered exercise/tax liability with 469 units of Ordinary Shares, increasing direct ownership by 2% to 33,217 units (SEC Form 4)
- SEC Form 4 filed by Interim President and CEO Manzone Albert
- Director Alford Bradley A exercised 976 units of Ordinary Shares at a strike of $10.99 and covered exercise/tax liability with 469 units of Ordinary Shares, increasing direct ownership by 1% to 45,465 units (SEC Form 4)
- SEC Form SD filed by Perrigo Company plc
- Former CEO and director Lockwood-Taylor Patrick exercised 25,230 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 12,906 units of Ordinary Shares, increasing direct ownership by 11% to 123,170 units (SEC Form 4)
- Perrigo Company plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- Perrigo Announces Leadership Transition
- EVP and President of CSCI Khoury Roberto exercised 17,902 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 9,346 units of Ordinary Shares, increasing direct ownership by 164% to 13,761 units (SEC Form 4)
- EVP & CHRO Willis Robert exercised 3,441 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 1,797 units of Ordinary Shares, increasing direct ownership by 3% to 50,568 units (SEC Form 4)
- EVP and CSO Lennox Abigail exercised 3,823 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 1,996 units of Ordinary Shares, increasing direct ownership by 66% to 4,607 units (SEC Form 4)